SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim® Insulin Pump, today presented the results of a research study that demonstrated faster training times and fewer errors when using the t:slim Pump versus a leading insulin pump. These data were presented at the 7 th Annual Advanced Technologies and Treatments for Diabetes (ATTD) International Conference in Vienna, Austria.
"Extensive human factors research went into the development of the t:slim Insulin Pump's intuitive touch screen user interface," said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. "We believe the shorter training times and reduced use errors observed in this study are a testament to the importance of this kind of research in medical device development."
The multi-center study looked at usability differences and training times for seven of the most common tasks performed on an insulin pump. Participants had never used an insulin pump before, and were using multiple daily injections of insulin for their current therapy (n=72). Subjects were randomized to train on either the t:slim Insulin Pump or the Medtronic® MiniMed® Paradigm Revel™ Insulin Pump. On the first visit of the study, participants were trained by a diabetes educator from the study site. On the second visit, which took place 24 to 48 hours later, participants performed the seven tasks without assistance. Study participants did not have access to the pump between visits. On average, the t:slim Pump took 27 percent less time to train than the Revel Pump (17.6 minutes vs. 24.1 minutes). The same users also experienced 65 percent fewer task failures (0.8 errors vs. 2.3 errors). A survey was administered at the end of the second visit to evaluate different aspects of the pump and training. Results showed that compared to the Revel Pump, the t:slim Pump used terminology that was easier to understand, had a screen with better contrast, was easier to read, was a better size, was easier to program, and was more enjoyable to use.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts